9 citations
,
April 2006 in “International Journal of Dermatology” DFMO may help control hair growth and treat cancer.
October 2021 in “European urology open science” January 2004 in “Actualidad en farmacología y terapéutica” Combining doxazosin and finasteride is more effective for managing benign prostatic hyperplasia than using either drug alone.
August 2021 in “Josai University Repository of Academia (Josai University)” The nanoparticles improved minoxidil's skin absorption, making them promising for skin treatments.
7 citations
,
April 2025 in “Science Advances” Silicate-based therapy may help treat inflammatory heart disease by reducing immune inflammation.
September 2025 in “Journal of Drug Delivery Science and Technology” Vitamin D3-coated nanoparticles effectively deliver caffeine for alopecia treatment with minimal side effects.
May 2024 in “Reactions weekly” May 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
4 citations
,
July 1987 in “Dermatologic Clinics”
Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.
14 citations
,
August 2015 in “Endocrinology” The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.
26 citations
,
March 2014 in “Rheumatology” Some drugs used to treat inflammation may cause hair loss.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
20 citations
,
May 2007 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Etanercept effectively treated a severe skin condition when other treatments failed.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
173 citations
,
July 2012 in “British Journal of Dermatology” Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
September 2025 in “International Journal of Innovative Technologies in Social Science” Dutasteride is more effective than finasteride for hair loss, but more research is needed on safety and dosing.
1 citations
,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
1 citations
,
January 2022 in “Brazilian Journal of Pharmaceutical Sciences” Minoxidil can be effectively encapsulated in coated nanovesicles for potential drug delivery.
February 2010 in “Journal of The American Academy of Dermatology” A woman with Degos disease managed her condition for nine years with medications and had two healthy pregnancies, while a separate finding suggests a possible link between female pattern hair loss and high blood pressure.
5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
March 2024 in “Journal of drugs in dermatology” HASHA is a safe and effective option for chin augmentation.
4 citations
,
January 2018 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Panitumumab can cause excessive ear hair growth.
5 citations
,
June 2001 in “Annals of Internal Medicine” Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.
28 citations
,
October 2010 in “Targeted Oncology” Trastuzumab may cause tufted hair folliculitis as a side effect.
1 citations
,
May 2025 in “BMC Cancer” CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
21 citations
,
September 2003 in “Journal of Clinical Investigation” Overexpressing noggin in mice causes severe osteoporosis.
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.